Advances in the Ocular Complications After Hematopoietic Stem Cell Transplantation

Overview

Journal Ann Hematol

Specialty Hematology

Date 2024 Feb 25

PMID 38403713

Authors

XiaoLi Lv

HuiBo Li

Sheng Su

ShengJin Fan

Affiliations

Soon will be listed here.

Abstract

Hematopoietic stem cell transplantation (HSCT) has benefited an increasing number of patients with hematological disease in the clinic. It is a curative therapy for malignant and nonmalignant hematological diseases. With the advancement and further clinical application of HSCT in recent years, the life expectancy of patients has increased, but complications have become more common. The occurrence of ocular complications is receiving increasing attention because they can seriously affect the quality of life of patients. Ocular complications require increased attention from clinicians because of their negative impact on patients and increasing incidence. Most of recent reports on posttransplant ocular complications involve ocular manifestations of graft-versus-host disease (GVHD), and a few ocular complications that do not originate from GVHD have also been reported. This review summarizes the diagnosis, scoring criteria, pathophysiology, and clinical manifestations of and common therapies for ocular graft-versus-host disease(oGVHD) after HSCT, and includes a description of some rare cases and novel therapies.

References

Inamoto Y, Chai X, Kurland B, Cutler C, Flowers M, Palmer J . Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology. 2011; 119(3):487-93. PMC: 3294118. DOI: 10.1016/j.ophtha.2011.08.040. View

Ogawa Y, Kim S, Dana R, Clayton J, Jain S, Rosenblatt M . International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part I). Sci Rep. 2013; 3:3419. PMC: 3851919. DOI: 10.1038/srep03419. View

Chatterjee D . A brief account on ocular graft versus host disease. Indian J Ophthalmol. 2023; 71(4):1115-1122. PMC: 10276667. DOI: 10.4103/IJO.IJO_2839_22. View

Carreno-Galeano J, Dohlman T, Kim S, Yin J, Dana R . A Review of Ocular Graft-versus-Host Disease: Pathophysiology, Clinical Presentation and Management. Ocul Immunol Inflamm. 2021; 29(6):1190-1199. DOI: 10.1080/09273948.2021.1939390. View

Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N . Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation. 1991; 51(6):1197-203. DOI: 10.1097/00007890-199106000-00010. View

Norton J, Sloane J . ICAM-1 expression on epidermal keratinocytes in cutaneous graft-versus-host disease. Transplantation. 1991; 51(6):1203-6. DOI: 10.1097/00007890-199106000-00011. View

Dustin M . Role of adhesion molecules in activation signaling in T lymphocytes. J Clin Immunol. 2001; 21(4):258-63. DOI: 10.1023/a:1010927208180. View

Shlomchik W . Antigen presentation in graft-vs-host disease. Exp Hematol. 2003; 31(12):1187-97. DOI: 10.1016/j.exphem.2003.09.017. View

Sharpe A, Freeman G . The B7-CD28 superfamily. Nat Rev Immunol. 2002; 2(2):116-26. DOI: 10.1038/nri727. View

10.

Korngold R, Sprent J . T cell subsets and graft-versus-host disease. Transplantation. 1987; 44(3):335-9. DOI: 10.1097/00007890-198709000-00002. View

11.

Lawley T, Peck G, Moutsopoulos H, Gratwohl A, Deisseroth A . Scleroderma, Sjögren-like syndrome, and chronic graft-versus-host disease. Ann Intern Med. 1977; 87(6):707-9. DOI: 10.7326/0003-4819-87-6-707. View

12.

Hollander G, Widmer B, Burakoff S . Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. J Immunol. 1994; 152(4):1609-17. View

13.

Beres A, Drobyski W . The role of regulatory T cells in the biology of graft versus host disease. Front Immunol. 2013; 4:163. PMC: 3690651. DOI: 10.3389/fimmu.2013.00163. View

14.

Vogelsang G, Lee L, Bensen-Kennedy D . Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med. 2002; 54:29-52. DOI: 10.1146/annurev.med.54.101601.152339. View

15.

Soleimani M, Mahdavi Sharif P, Cheraqpour K, Koganti R, Masoumi A, Baharnoori S . Ocular graft-versus-host disease (oGVHD): From A to Z. Surv Ophthalmol. 2023; 68(4):697-712. PMC: 10293080. DOI: 10.1016/j.survophthal.2023.02.006. View

16.

Nair S, Vanathi M, Mahapatra M, Seth T, Kaur J, Velpandian T . Tear inflammatory mediators and protein in eyes of post allogenic hematopoeitic stem cell transplant patients. Ocul Surf. 2018; 16(3):352-367. DOI: 10.1016/j.jtos.2018.04.007. View

17.

He J, Ogawa Y, Mukai S, Saijo-Ban Y, Kamoi M, Uchino M . In Vivo Confocal Microscopy Evaluation of Ocular Surface with Graft-Versus-Host Disease-Related Dry Eye Disease. Sci Rep. 2017; 7(1):10720. PMC: 5587759. DOI: 10.1038/s41598-017-10237-w. View

18.

Dietrich-Ntoukas T, Cursiefen C, Westekemper H, Eberwein P, Reinhard T, Bertz H . Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD. Cornea. 2011; 31(3):299-310. DOI: 10.1097/ICO.0b013e318226bf97. View

19.

Kim S . Update on ocular graft versus host disease. Curr Opin Ophthalmol. 2006; 17(4):344-8. DOI: 10.1097/01.icu.0000233952.09595.d8. View

20.

Balaram M, Rashid S, Dana R . Chronic ocular surface disease after allogeneic bone marrow transplantation. Ocul Surf. 2006; 3(4):203-11. DOI: 10.1016/s1542-0124(12)70207-0. View